Exploring possible uses of modern molecular biology and cell technologies in the treatment of disease.

OcuNexus Therapeutics focuses on the development of treatments for diseases where the inflammasome pathway of inflammation is dysregulated. The company's main product is a small molecule, administered orally once a day, that targets the pathologically open Connexin43 hemichannel, which is responsible for inflammasome-mediated autoinflammation in several disease states. The company primarily sells to the ophthalmology and nephrology sectors, with a focus on conditions such as diabetic retinopathy, diabetic nephropathy, and the intermediate stage of macular degeneration. OcuNexus Therapeutics was formerly known as CoDa Therapeutics. It was founded in 2005 and is based in San Diego, California.

Intarcia Therapeutics is a biotech company that focuses on the development of biologics and peptides for the treatment of cardio-renal-metabolic diseases. The company's main offerings include a pipeline of long-acting GLP-1 receptor agonists and other peptide-based therapies designed to improve the management of chronic diseases. Intarcia primarily serves sectors in the healthcare industry that are involved with chronic disease management and biopharmaceuticals. It was founded in 1995 and is based in Boston, Massachusetts.

Kardia Therapeutics, Inc. is a research-stage biotechnology company focused on the development of cardiac regenerative therapies in the areas myocardial infarction and heart failure. Kardia Therapeutics' portfolio of technologies aims to utilize three related approaches: 1) Adult Cardiac Progenitor Cells, 2) Stem Cell Optimization Technologies, and 3) Homing/Growth Factor Therapies. Because the heart has a limited capacity for self-regeneration, Kardia's technologies have the potential to offer improved patient outcomes compared to existing treatments.

APT Therapeutics is a biopharmaceutical company focused on developing treatments for thrombotic diseases. The company offers a product, APT-102, which is indicated for conditions such as heart attack, stroke, acute lung injury, and pulmonary arterial hypertension. It was founded in 2001 and is based in Saint Louis, Missouri.

Stemina Biomarker Discovery specializes in the development of in vitro toxicity assays and biomarker discovery to improve drug safety and human health. The company offers assays that predict developmental and cardiotoxicity using human cell-based endpoints and a metabolomics platform. Stemina also provides a diagnostic test for autism spectrum disorder through its NeuroPointDX division. It was founded in 2006 and is based in Madison, Wisconsin.